New Multiple Sclerosis Treatments 2021



Article last updated on 4/1/2021

What is Multiple Sclerosis?1,2


Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. The body’s immune system incorrectly attacks and damages the protective sheath around the nerve cells in the central nervous system (the brain and spinal cord). For most people with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions). Over time, recovery may be incomplete, leading to progressive decline in function and increased disability.


Is there a cure for Multiple Sclerosis?


There is currently no cure for Multiple Sclerosis. Existing treatments aim to help patients manage symptoms.


What are new MS drugs in development?


There are currently several MS experimental treatments under clinical trials currently. For a complete list, visit the https://mstrust.org.uk/about-ms/ms-treatments/drugs-development MS Trust organisation website here.


What are the newest Multiple Sclerosis treatments?


Several medicines have been approved for the treatment of Multiple Sclerosis. Here are some of the newest medicines for Multiple Sclerosis:


Zeposia (ozanimod)3,4,5,6,7

Zeposia (ozanimod) is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS).

Zeposia (ozanimod) was approved for the treatment of adults with RRMS by:

  • The Food and Drug Administration (FDA), USA, on March 26, 2020.
  • The European Medicines Agency (EMA), Europe, on May 20, 2020.
  • The Therapeutic Goods Administration (TGA), Australia, on July 27, 2020.
  • Health Canada, Canada, on October 7, 2020.

It is the only approved S1P receptor modulator that does not require a genetic test or first-dose observation.


Kesimpta (ofatumumab)8,9

Kesimpta (ofatumumab) is a CD20-directed cytolytic antibody (immunotherapy) indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Kesimpta (ofatumumab) was approved for the treatment of adult patients with relapsing forms of MS by the Food and Drug Administration (FDA), USA on August 20, 2020.


Mayzent (siponimod)10,11,12,13

Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator and is used for the treatment of adults with multiple sclerosis, and specifically active secondary progressive multiple sclerosis (SPMS). This is the first oral treatment specifically for active SPMS, which encompasses about 80% of relapsing remitting multiple sclerosis (RRMS) cases.

Mayzent (siponimod) was approved for multiple sclerosis by:

  • Food and Drug Administration (FDA), US, March 26, 2019 Therapeutic Goods Administration (TGA), Australia, November 1, 2019
  • European Medical Agency (EMA), European Union, January 13, 2020

If you’ve received a Multiple Sclerosis diagnosis and are trying to access a new Multiple Sclerosis drug that is approved outside of your country of residence, we might be able to help you access it with the help of your treating doctor. You can read more about the medicines we can help you access and their price below:




Why buy new treatments for Multiple Sclerosis with TheSocialMedwork?


TheSocialMedwork is registered in The Hague with the Dutch Ministry of Health (registration number 6730 BEM) as an independent medicines intermediary. We have helped patients from over 85 countries to access thousands of medicines including. With a prescription from your treating doctor, you can count on our expert team to safely and legally guide you to access a new medication for Multiple Sclerosis. If you or someone you know are looking to access a medicine that is not yet approved where they live, we can support you. Contact us for more information.


References:

  1. Fda.gov
  2. Ema.europa.eu
  3. Accessdata.fda.gov
  4. News.bms.com
  5. Ema.europa.eu
  6. Tga.gov.au
  7. Newswire.ca
  8. Accessdata.fda.gov
  9. Novartis.com
  10. Accessdata.fda.gov
  11. Novartis.com
  12. Ebs.tga.gov.au
  13. Ema.europa.eu

Disclaimer: This article is not meant to influence or impact the care provided by your treating physician. Please do not make changes to your treatment without first consulting your healthcare provider. This article is not intended to diagnose or treat illness or to influence treatment options. TheSocialMedwork is as diligent as possible in compiling and updating the information on this page. However, TheSocialMedwork does not guarantee the correctness and completeness of the information provided on this page.